The Turkish Journal of Pharmaceutical Sciences is an independent journal with independent editors and principles and has no commercial relationship with the commercial product, drug or pharmaceutical company regarding decisions and review processes upon articles.

Editorial Independence

The Turkish Journal of Pharmaceutical Sciences is an independent journal with independent editors and principles and has no commercial relationship with the commercial product, drug or pharmaceutical company regarding decisions and review processes upon articles.

ABSTRACTED/INDEXED IN

PubMed Central
Web of Science-Emerging Sources Citation Index (ESCI)
SCOPUS SJR
TÜBİTAK/ULAKBİM TR Dizin
Directory of Open Access Journals (DOAJ)
ProQuest
Chemical Abstracts Service (CAS)
EBSCO
EMBASE
Gale
Index Copernicus
Analytical Abstracts
International Pharmaceutical Abstracts (IPA)
Medicinal & Aromatic Plants Abstracts (MAPA)
British Library
CSIR INDIA
GOALI
HiNARI
OARE
ARDI
AGORA
Türkiye Arifi Dizini
Türk Medline
UDL-EDGE
J-Gate
Ideaonline
ROOTINDEXING
CABI

OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) http://www.budapestopenaccessinitiative.org/. By “open access” to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

CORRESPONDENCE ADDRESS

All correspondence should be directed to the Turkish Journal of Pharmaceutical Sciences editorial board;

Post Address: Turkish Pharmacists’ Association, Mustafa Kemal Mah 2147.Sok No:3 06510 Çankaya/Ankara, TURKEY
Phone: +90 (312) 409 81 00
Fax: +90 (312) 409 81 09
Web Page: http://turkjps.org
E-mail: info@galenos.com.tr

PERMISSIONS

Requests for permission to reproduce published material should be sent to the publisher.

Publisher: Erkan Mor
Adress: Molla Gürani Mah. Kaçamak Sok. 21/1 Fındıkzade, Fatih, İstanbul, Turkey
Telephone: +90 212 621 99 25
Fax: +90 212 621 99 27
E-mail: info@galenos.com.tr

ISSUING BODY CORRESPONDING ADDRESS

Issuing Body : Galenos Yayınevi
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1, 34093 İstanbul, Turkey
Phone: +90 212 621 99 25 Fax: +90 212 621 99 27
E-mail: info@galenos.com.tr

MATERIAL DISCLAIMER

The author(s) is (are) responsible for the articles published in the JOURNAL. The editor, editorial board and publisher do not accept any responsibility for the articles.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
INSTRUCTIONS TO AUTHORS

Turkish Journal of Pharmaceutical Sciences journal is published 6 times (February, April, June, August, October, December) per year and publishes the following articles:

- Research articles
- Reviews (only upon the request or consent of the Editorial Board)
- Preliminary results/Short communications/Technical notes/Letters to the Editor in every field of pharmaceutical sciences.

The journal is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation reviews the manuscript and makes an initial decision based on manuscript review principles. The manuscript is assigned to the Editor-in-Chief, who.

The Review Process

This is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief assigns an Associate Editor. The Associate Editor sends the manuscript to at least two reviewers (internal and/or external reviewers). The Associate Editor recommends a decision based on the reviewers’ recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

The scientific board guiding the selection of the papers to be published in the Turkish Journal of Pharmaceutical Sciences does not charge any article submission or processing charges.

The journal is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who.

A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere.

The Journal should be abbreviated as “Turk J Pharm Sci” when referenced.

The scientific and ethical liability of the manuscripts belongs to the authors and the copyright of the manuscripts belongs to the Journal. Authors are responsible for the contents of the manuscript and accuracy of the references. All manuscripts submitted for publication must be accompanied by the Copyright Transfer Form (copyright transfer). Once this form, signed by all the authors, has been submitted, it is understood that neither the manuscript nor the data it contains have been submitted elsewhere or previously published and authors declare the statement of scientific contributions and responsibilities of all authors.

Experimental, clinical and drug studies requiring approval by an ethics committee must be submitted to the journal with an ethics committee approval report including approval number confirming that the study was conducted in accordance with international agreements and the Declaration of Helsinki (revised 2013) (http://www.wma.net/en/30publications/10policies/b3/). The approval of the ethics committee and the fact that informed consent was given by the patients should be indicated in the Materials and Methods section. In experimental animal studies, the authors should indicate that the procedures followed were in accordance with animal rights as per the Guide for the Care and Use of Laboratory Animals (http://oauz.od.nih.gov/regs/guide/guide.pdf) and they should obtain animal ethics committee approval.

Authors must provide disclosure/acknowledgment of financial or material support, if any was received, for the current study.

If the article includes any direct or indirect commercial links or if any institution provided material support to the study, authors must state in the cover letter that they have no relationship with the commercial product, drug, pharmaceutical company, etc. concerned; or specify the type of relationship (consultant, other agreements), if any. Authors must provide a statement on the absence of conflicts of interest among the authors and provide authorship contributions.

All manuscripts submitted to the journal are screened for plagiarism using the ‘iThenticate’ software. Results indicating plagiarism may result in manuscripts being returned or rejected.

The Review Process

This is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief assigns an Associate Editor. The Associate Editor sends the manuscript to at least two reviewers (internal and/or external reviewers). The Associate Editor recommends a decision based on the reviewers’ recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

The scientific board guiding the selection of the papers to be published in the Journal consists of elected experts of the Journal and if necessary, selected from national and international authorities. The Editor-in-Chief, Associate Editors may make minor corrections to accepted manuscripts that do not change the main text of the paper.

In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the Journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. The Journal accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.


Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:

- STROBE statement, a checklist of items that should be included in reports of observational studies (http://www.strobe-statement.org/);

GENERAL GUIDELINES

Manuscripts can only be submitted electronically through the Journal Agent website (http://journalagent.com/tips/) after creating an account. This system allows online submission and review.
Format: Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.

Abbreviations: Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.

Cover letter: The cover letter should include statements about manuscript type, single-Journal submission affirmation, conflict of interest statement, sources of outside funding, equipment (if applicable), for original research articles.

ETHICS COMMITTEE APPROVAL
The editorial board and our reviewers systematically ask for ethics committee approval from every research manuscript submitted to the Turkish Journal of Pharmaceutical Sciences. If a submitted manuscript does not have ethical approval, which is necessary for every human or animal experiment as stated in international ethical guidelines, it must be rejected on the first evaluation.

Research involving animals should be conducted with the same rigor as research in humans; the Turkish Journal of Pharmaceutical Sciences asks original approval documentation to show that all research involving animals is conducted in compliance with the 3Rs (replace, reduce, refine) principles. If a study does not have ethics committee approval or authors claim their study does not need approval, the study is consulted and evaluated by the editorial board for approval.

SIMILARITY
The Turkish Journal of Pharmaceutical Sciences is routinely looking for similarity index score from every manuscript submitted before evaluation by the editorial board and reviewers. The journal uses iThenticate plagiarism checker software to verify the originality of written work. There is no acceptable similarity index; but, exceptions are made for similarities less than 15 %.

REFERENCES
Authors are solely responsible for the accuracy of all references.

In-text citations: References should be indicated as a superscript immediately after the period/full stop of the relevant sentence. If the author(s) of a reference is/are indicated at the beginning of the sentence, this reference should be written as a superscript immediately after the author’s name. If relevant research has been conducted in Turkey or by Turkish investigators, these studies should be given priority while citing the literature.

Presentations presented in congresses, unpublished manuscripts, theses, Internet addresses, and personal interviews or experiences should not be indicated as references. If such references are used, they should be indicated in parentheses at the end of the relevant sentence in the text, without reference number and written in full, in order to clarify their nature.

References section: References should be numbered consecutively in the order in which they are first mentioned in the text. All authors should be listed regardless of number. The titles of Journals should be abbreviated according to the style used in the Index Medicus.

References:

Book: Last name(s) of the author(s) and initials, book title, edition, place of publication, date of publication and inclusive page numbers of the extract cited.


Book Chapter: Last name(s) of the author(s) and initials, chapter title, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.


Books in which the editor and author are the same person: Last name(s) of the author(s) and initials, chapter title, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.


TABLES, GRAPHICS, FIGURES, AND IMAGES
All visual materials together with their legends should be located on separate pages that follow the main text.

Images: Images (pictures) should be numbered and include a brief title. Permission to reproduce pictures that were published elsewhere must be included. All pictures should be of the highest quality possible, in JPEG format, and at a minimum resolution of 300 dpi.

Tables, Graphics, Figures: All tables, graphics or figures should be enumerated according to their sequence within the text and a brief descriptive caption should be written. Any abbreviations used should be defined in the accompanying legend. Tables in particular should be explanatory and facilitate readers’ understanding of the manuscript, and should not repeat data presented in the main text.

MANUSCRIPT TYPES
Original Articles
Clinical research should comprise clinical observation, new techniques or laboratories studies. Original research articles should include title, structured abstract, key words relevant to the content of the article, introduction, materials and methods, results, discussion, study limitations, conclusion references, tables/figures/images and acknowledgement sections. Title, abstract and key words should be written in both Turkish and English. The manuscript should be formatted in accordance with the above-mentioned guidelines and should not exceed 16 A4 pages.

Title Page: This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:
1. Title of the manuscript (Turkish and English), as concise and explanatory as possible, including no abbreviations, up to 135 characters
2. Short title (Turkish and English), up to 60 characters
3. Name(s) and surname(s) of the author(s) (without abbreviations and academic titles) and affiliations
4. Name, address, e-mail, phone and fax number of the corresponding author
5. The place and date of scientific meeting in which the manuscript was presented and its abstract published in the abstract book, if applicable

Abstract: A summary of the manuscript should be written in both Turkish and English. References should not be cited in the abstract. Use of abbreviations should be avoided as much as possible; if any abbreviations are used, they must be taken into consideration independently of the abbreviations used in the text. For original articles, the structured abstract should include the following sub-headings:

Objectives: The aim of the study should be clearly stated.

Materials and Methods: The study and standard criteria used should be defined; it should also be indicated whether the study is randomized or not, whether it is retrospective or prospective, and the statistical methods applied should be indicated, if applicable.

Results: The detailed results of the study should be given and the statistical significance level should be indicated.

Conclusion: Should summarize the results of the study, the clinical applicability of the results should be defined, and the favorable and unfavorable aspects should be declared.

Keywords: A list of minimum 3, but no more than 5 key words must follow the abstract. Key words in English should be consistent with “Medical Subject Headings (MESH)” (www.nlm.nih.gov/mesh/MBrowser.html). Turkish key words should be direct translations of the terms in MESH.

Original research articles should have the following sections:

Introduction: Should consist of a brief explanation of the topic and indicate the objective of the study, supported by information from the literature.

Materials and Methods: The study plan should be clearly described, indicating whether the study is randomized or not, whether it is retrospective or prospective, the number of trials, the characteristics, and the statistical methods used.

Results: The results of the study should be stated, with tables/figures given in numerical order; the results should be evaluated according to the statistical analysis methods applied. See General Guidelines for details about the preparation of visual material.

Discussion: The study results should be discussed in terms of their favorable and unfavorable aspects and they should be compared with the literature. The conclusion of the study should be highlighted.

Study Limitations: Limitations of the study should be discussed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

Conclusion: The conclusion of the study should be highlighted.

Acknowledgements: Any technical or financial support or editorial contributions (statistical analysis, English/Turkish evaluation) towards the study should appear at the end of the article.

References: Authors are responsible for the accuracy of the references. See General Guidelines for details about the usage and formatting required.

Review Articles

Review articles can address any aspect of clinical or laboratory pharmaceuticals. Review articles must provide critical analyses of contemporary evidence and provide directions of or future research. Most review articles are commissioned, but other review submissions are also welcome. Before sending a review, discussion with the editor is recommended.

Reviews articles analyze topics in depth, independently and objectively. The first chapter should include the title in Turkish and English, an unstructured summary and key words. Source of all citations should be indicated. The entire text should not exceed 25 pages (A4, formatted as specified above).
### Letter to Editor

250 Administration of Potential Medications for COVID-19 Treatment Through Feeding Tube

**COVID-19 Tedavisi için Kullanılan Potansiyel İlaçların Beslenme Tüpünden Uygulanması**

Burcu KELLECİ ÇAKIR, Oğuzhan FIRAT, Kutay DEMİRKAN

### Original Articles

252 Strategic Analysis of the Turkish Over-the-Counter Drugs and Non-pharmaceutical Products Market

**Türkiye Tezgah Üstü İlaç ve İlaç Dışı Ürün Pazaranın Stratejik Analizi**

Merve MEMİŞOĞLU, Ömer BİLEN

262 Granny Smith Apple Extract Lowers Inflammation and Improves Antioxidant Status in L-arginine-induced Exocrine Pancreatic Dysfunction in Rats

**Granny Smith Elma Ekstresi, Sıçanlarda L-arginin Kaynaklı Ekzokrin Pankreas Bozukluğunda İnflamasyonuzu Azaltır ve Antioksidan Durumunu İyileştirir**

Gadicherla VEENA, Siva Reddy CHALLA, Sujatha PALATHEEYA, Ramakrishna PRUDHIVI, Anitha KADARI

271 Cardioprotective Effect of *Marsdenia tenacissima* and *Sansevieria roxburghiana* in Doxorubicin-induced Cardiotoxicity in Rats in vivo: The Role of Dresgenin and Lupeol

**Sıçanlarda Doktorubisin Kaynaklı Kardiyotoksisitede Marsdenia tenacissima ve Sansevieria roxburghiana’nın in vivo Kardiyoprotetik Etkisi: Dresgenin ve Lupeol’un Rolü**

Aparna Ann MATHEW, Raju ASIRVATHAM, Dawn V TOMY

282 Evaluation of Prescribing Patterns of Antibiotics Using Selected Indicators for Antimicrobial Use in Hospitals and the Access, Watch, Reserve (AWaRe) Classification by the World Health Organization

**Hastanelerde Antimikrobiyal Kullanımı ile İlgili Seçilmiş Göstergeler ve Dünya Sağlık Örgütü Tarafından Tanımlanan AWaRe Sınıflandırması Kullanılarak Antibiyotik Reçeteleme Kalıplarının Değerlendirilmesi**

Vinodkumar MUGADA, Varsha MAHATO, Damayanthi ANDHAVARAM, Sairam Mouli VAJHALA

289 Characteristic Comparison of an Intraoral Thin Film Containing Astaxanthin Nanoemulsion Using Sodium Alginate and Gelatin Polymers

**Sodyum Aljinat ve Jelatin Polimerleri Kullanılmış Nanoemülsiyon Astaksantin İçeren İntraoral İnce Filmin Karakteristiğinin Karşılaştırılması**

Lusi NURDIANTI, Taofik RUSDIANA, Iyan SOPYAN, Norisca Aliza PUTRIANA, Hanifa Rirdah AIMAN, Tengku Ruhul FAJRIA

296 A Novel Analytical Method for the Simultaneous Estimation of Remogliflozin and Metformin Hydrochloride by UPLC/PDA in Bulk and Formulation Application to the Estimation of Product Traces

**Bulk ve Formülasyon Uygulamalarında Eser Ürünlerin Kestirimi için UPLC/PDA ile Remogliflozin ve Metformin Hidroklorürü Ez zamanlı Belirleyebilen Yeni Bir Analitik Yöntem**

Mohan Rao TAMMISETTY, Balasekharra Reddy CHALLA, Srinivasa Babu PUTTAGUNTA

306 Development and Validation of an HPLC Method Using an Experimental Design for Analysis of Amlodipine Besylate and Enalapril Maleate in a Fixed-dose Combination

**Amlodipin Besylate ve Enalapril Maleatin Sabit Dozlu Kombinasyondan Analizi için Deney Tasarımı Yoluyla Bir YBSK Yöntemi Gelişirilmesi ve Validasyonu**

Diren SARIALTIK YAŞIN, Alev ARSLANTÜRK BİNGÜL, Alptuğ KARAKÜÇÜK, Zeynep Şafak TEKSİN

319 Preclinical Study on the Hepatoprotective Effect of Pollen Extract of *Pinus brutia* Ten. (Red Pine) in Mice and Phenolic Acid Analysis

**Pinus brutia Ten. (Kızılçam) Polen Ekstresinin Karaciğer Koruyucu Etkisinin Preklinik Olarak Araştırılması ve Fenolik Asit Analizleri**

Hasya Nazlı GÖK, Hina GÜL, Muhammad GÜLFRAZ, Muhammad Javaid ASAD, Nilgün ÖZTÜRK, Fuat ŞANAL, İlay Erdoğan ORHAN
326 Prophylaxis and Therapeutic Ability of Inactivated Dermatophytic Vaccine Against Dermatophytosis in the Rabbits as an Animal Model
Bir Hayvan Modeli Olarak Tavşanlarda Dermatofitoza Karşı İnaktive Dermatofitik Aşının Profilaksi ve Terapötik Yeteneği
Ali Abdul Hussein S. AL-JANABI, Falah Hasan Obayes AL-KHIKANI

332 Hepatoprotective Activity of Gentisic Acid on 5-Fluorouracil-induced Hepatotoxicity in Wistar Rats
Wistar Sıçanlarında Gentişik Asidin 5-Florourasil Kaynaklı Hepatotoksisite Üzerindeki Hepatoprotektif Aktivitesi
Rohini Revansiddappa PUJARI, Deepti Dinesh BANDAWANE

339 Voltametric Determination of Zoledronic Acid in a Pharmaceutical Formulation
Farmasötik Bir Formülasyonda Zoledronik Asidin Voltametrik Tayini
Abdulaziz AMRO, Samer RATROUT, Fadi ASFOUR

344 Development and Evaluation of Solid Witepsol Nanoparticles for Gene Delivery
Gen Taşınımı için Katı Witepsol Nanopartiküllerinin Geliştirilmesi ve Değerlendirilmesi
Gülşah EREL-AKBABA, Selen İSAR, Hasan AKBABA

352 Development and Rheological Evaluation of DEET (N,N-Diethyl-3-Methylbenzamide) Microparticles Loaded Hydrogel For Topical Application
Topikal Uygulama İçin DEET (N,N-Dietil-3-Metilbenzamid) Mikropartikül Yüklenmiş Hidrojel Geliştirilmesi ve Reolojik Değerlendirilmesi
Rajesh SREEDHARAN NAIR, Habibur RAHMAN, Min Xian KONG, Xin Yi TAN, Kah Yin CHEN, Suresh SHANMUGHAM

360 Assessment of Protective Effects of Methanolic Extract of Salvia verbenaca Roots Against Oxidative Damage Induced by Hydrogen Peroxide
Hidrojen Peroksitin Neden Olduğu Oksidatif Hasara Karşı Salvia verbenaca Köklerinin Metanol Ekstresinin Koruyucu Etkilerinin Değerlendirilmesi
Meryem NASSAR, Fethia ZADRI, Souheila SLIMANI

367 Development of Polylactic Acid and Bovine Serum Albumin-layered-coated Chitosan Microneedles Using Novel Bees Wax Mould
Yeni Balmumu Kalıbı Kullanılarak Polilaktik Asit ve Sığır Serum Albümin Tabakalı Kaplanmış Kitosan Mikroiğnelerinin Geliştirilmesi
Ravindra V BADHE, Deepak ADKINE, Anagha GODSE

Review

376 Mechanistic Biomarkers in Toxicology
Tokxikolojide Mekanistik Biyobelirteçler
Sonia SANAJOU, Gönül ŞAHİN